<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395485</url>
  </required_header>
  <id_info>
    <org_study_id>20101281</org_study_id>
    <nct_id>NCT01395485</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescent (12 to &lt;18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics in
      adolescent and adult subjects with intermittent or mild to moderate persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study had been cancelled and replaced with protocol 20130250.
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adolescent subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the AMG 827 concentration versus time curve (AUC) for times 0 to infinity (AUC 0-inf) and 0 to last sampling time point (AUC 0-tlast), peak plasma concentration (Cmax) and Time to peak plasma concentration (tmax) will be determined for AMG 827</measure>
    <time_frame>Intermittantly throughout the duration of the study, an expected average of 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adult subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability</measure>
    <time_frame>Intermittantly throughout the duration of the study, an expected average of 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents - Ages 13 to &lt;17</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents - Ages 12 to &lt;13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults - Ages 18 to &lt;=50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents - Ages 17 to &lt;18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827 or Placebo</intervention_name>
    <description>A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female subjects 12 to &lt; 18 years of age at the time of randomization

          -  Male and/or female subjects between 18 and 50 years of age (inclusive) at the time of
             randomization

          -  Body weight â‰¥ 36 kg at screening

          -  Intermittent or mild to moderate persistent asthma for at least the past 3 months
             prior to study enrollment (as defined by the 2004 Global Initiative for Asthma [GINA]
             guidelines.

        Exclusion Criteria:

          -  Experienced an asthma exacerbation (defined as a disease episode resulting in
             treatment in an emergency room or urgent care facility, or an episode treated with
             oral corticosteroids) during the 3 months prior to study enrollment.

          -  Hospitalized for asthma during the 6 months prior to study enrollment; or ever
             intubated for the treatment of asthma.

          -  Use of oral corticosteroids within 3 months prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Single Dose</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

